This Masterclass for UPSC Drug Inspector 2026 covers Hospital & Clinical Pharmacy, essential for CDSCO exams. It details hospital organization, critical inventory management formulas (ABC, VED, EOQ), legal requirements for Schedule H1/Narcotics, a crucial TDM drug list with ranges, ADR classification, and NABH accreditation standards. Key concepts and their application are presented for exam readiness.
SECTION 1: HOSPITAL PHARMACY — ORGANIZATION & STRUCTURE
1.1 Classification of Hospitals
- Primary (PHC/CHC)
- Secondary (District Hospital)
- Tertiary (Medical College/Super-specialty)
- Bed strength categorization affects pharmacy staffing norms (per Indian Public Health Standards, IPHS)
1.2 Functions of Hospital Pharmacy Department
- Procurement & inventory management
- Storage & distribution of drugs/consumables
- Manufacturing/repackaging (small-scale, extemporaneous)
- Quality assurance & quality control
- Clinical pharmacy services
- Drug information services
- Education & training (pharmacy students, interns, nursing staff)
- ADR monitoring & reporting
- Participation in hospital committees
1.3 Committees (High-yield)
- Pharmacy & Therapeutics Committee (PTC)/Drug & Therapeutics Committee (DTC): Multidisciplinary advisory body (physicians, pharmacists, nurses, microbiologist, administrator); maintains and reviews Hospital Formulary; evaluates new drug requests; reviews ADR/medication error reports
- Infection Control Committee: Antibiotic policy, hospital-acquired infection (HAI) surveillance
- Hospital Ethics Committee: Clinical trial oversight, informed consent review
- Biomedical Waste Management Committee
- Antimicrobial Stewardship Committee: Restricted antibiotic list, culture-based prescribing
1.4 Hospital Formulary System
- Hospital Formulary: Continually revised compilation of pharmaceuticals reflecting current clinical judgment of medical staff
- Types: Open formulary (any drug allowed), Closed formulary (only listed drugs stocked), Restricted formulary (certain drugs need special approval)
- Reviewed and updated periodically (typically annually) by PTC
SECTION 2: INVENTORY MANAGEMENT (Very high-yield, formula-based)
Exam Tip: This section is very high-yield, often featuring formula-based questions. Memorize all formulas and their components.
2.1 ABC Analysis (Always Better Control)
- Based on annual consumption value (cost × usage), not quantity
- Category A: ~10–20% of items, ~70–80% of total value → tight control, frequent review
- Category B: ~20–30% of items, ~15–20% of value → moderate control
- Category C: ~50–70% of items, ~5–10% of value → loose control, bulk ordering
2.2 VED Analysis (Criticality-based)
- Vital: Life-saving, stock-out unacceptable (e.g., emergency drugs, antidotes)
- Essential: Important but brief stock-out tolerable
- Desirable: Stock-out has minimal impact
2.3 Combined ABC-VED Matrix
- Used to prioritize items where both cost and criticality matter (e.g., "AV" category = highest priority)
2.4 FSN Analysis
- Fast-moving, Slow-moving, Non-moving — based on consumption rate/frequency, used to identify obsolete stock
2.5 HML Analysis
- High, Medium, Low cost per unit — used for price-based control
2.6 SDE Analysis
- Scarce, Difficult, Easy — based on availability/procurement difficulty
2.7 Key Inventory Formulas (Memorize)
Exam Tip: Memorize these formulas for potential numerical problems.
- Economic Order Quantity (EOQ): EOQ = √(2DS/H)
- D = Annual demand
- S = Ordering cost per order
- H = Holding cost per unit/year
- Reorder Level (ROL): ROL = (Average daily usage × Lead time) + Safety stock
- Safety Stock: Buffer stock to prevent stock-out during lead time variability
- Maximum Stock Level: ROL + EOQ − (Min. usage × Min. lead time)
- Minimum Stock Level: ROL − (Average usage × Average lead time)
- Danger Level: Level at which emergency purchase is triggered = Avg. daily consumption × Max. lead time (for emergency procurement)
- Inventory Turnover Ratio: Annual consumption value ÷ Average inventory value (higher ratio = efficient stock use)
- Lead Time: Time gap between placing order and receiving stock
2.8 Procurement Methods
- Open tender, limited tender, single tender, rate contract (Central Purchase Organization), quotation, direct purchase (emergency)
- GeM (Government e-Marketplace): Used for govt. hospital procurement in India
SECTION 3: DRUG DISTRIBUTION SYSTEMS
3.1 Types (Detailed)
- Floor Stock (Ward Stock) System: Bulk supply on ward; nurse administers directly; advantage = immediate availability; disadvantage = high pilferage/error risk, no pharmacist verification, drug deterioration risk
- Individual Prescription Order System: Pharmacist dispenses per written Rx for each patient; good clinical control; disadvantage = delay, more pharmacist time/staff needed
- Unit Dose Dispensing System (UDDS): Single unit, ready-to-administer dose supplied for 24 hours; pharmacist reviews every medication order before dispensing
- Advantages: Reduces medication errors (~50% reduction documented), reduces wastage/pilferage, accurate billing, better inventory control, pharmacist clinical intervention on each order
- Disadvantages: High initial cost, needs more pharmacist/technician time, packaging infrastructure required
- Combination/Modified systems: Ward stock for emergency drugs + UDDS for regular medication (most Indian tertiary hospitals use this hybrid)
- Automated Dispensing Cabinets (ADC): Pyxis/Omnicell — electronic, decentralized, controlled-substance tracking, real-time inventory
- Centralized vs Decentralized/Satellite Pharmacy: Satellite pharmacies (near ICU/OT/Emergency) reduce turnaround time, improve clinical integration
3.2 Special Distribution Systems
- Emergency/Crash Cart drugs: Standardized list, sealed, checked daily/shift-wise, tamper-evident lock with log
- Controlled/Narcotic drug distribution: Double-lock system, register maintained as per NDPS Rules, balance verified each shift
- Investigational drug/clinical trial drug storage: Separate, temperature-controlled, dedicated to trial per ICH-GCP requirements
SECTION 4: CENTRAL STERILE SUPPLY & IV ADMIXTURE SERVICES
4.1 Central Sterile Supply Department (CSSD)
- Function: Cleaning, disinfection, sterilization, storage, and distribution of reusable medical/surgical items
- Sterilization methods used: Autoclave (steam), ETO (ethylene oxide) for heat-sensitive items, dry heat, plasma sterilization
4.2 IV Admixture Services / Sterile Compounding
- Laminar Air Flow (LAF) cabinet: Horizontal (for general sterile products) vs Vertical/Biosafety cabinet (for hazardous/cytotoxic drugs — protects operator)
- Aseptic technique mandatory; environmental monitoring (particle counts, microbial sampling)
- Total Parenteral Nutrition (TPN): Compounded centrally; contains dextrose, amino acids, lipids, electrolytes, trace elements, vitamins; stability/compatibility checks critical (Ca-Phosphate precipitation risk)
- Cytotoxic/Chemotherapy drug handling: Biological Safety Cabinet (Class II), PPE (gown, double gloves, respirator), spill kit mandatory, closed-system transfer devices (CSTDs)
4.3 Extemporaneous Compounding/Dispensing
- Preparation of formulations not commercially available (e.g., pediatric suspensions from tablets)
- Beyond-use dating (BUD) must be assigned based on stability data/USP guidelines
SECTION 5: PRESCRIPTION & LEGAL REQUIREMENTS
5.1 Parts of Prescription
- Superscription (Rx symbol), Inscription (drug/strength), Subscription (dispensing instruction), Signatura (patient directions), prescriber details, date, patient details
5.2 Schedule-wise Legal Requirements (D&C Rules — cross-link with Subject 1)
- Schedule H: Prescription-only drugs; label must bear "Schedule H — Prescription drug — Caution: Not to be sold by retail without the prescription of a Registered Medical Practitioner"
- Schedule H1: Antibiotics/habit-forming drugs (introduced 2013); mandatory to record patient name, address, prescriber name/registration no. in a separate register retained for 3 years; label bears Schedule H1 symbol (Rx in red box) and warning
- Schedule X: Narcotic/psychotropic drugs; prescription in duplicate, one copy retained by chemist for 2 years, special register required
5.3 Common Prescription/Medication Errors
- Illegible handwriting, wrong abbreviation (e.g., "U" mistaken for "0"), incomplete Sig, LASA (Look-Alike Sound-Alike) drugs, wrong route, transcription error, omission error
- Tall Man Lettering: Prevention technique for LASA drugs (e.g., DOBUTamine vs DOPamine)
- Medication Reconciliation: Process of comparing patient's current medication list with new orders at transitions of care (admission/transfer/discharge) to avoid discrepancies
SECTION 6: PATIENT COUNSELLING & CLINICAL PHARMACY SERVICES
6.1 Patient Counselling — Key Points
- Drug name & purpose, dose/route/frequency/duration, special instructions (food interaction, timing), storage, missed-dose action, side effects to watch, drug/food interactions
6.2 Clinical Pharmacy Services (Ward-level)
- Ward Round Participation: Clinical pharmacist attends rounds, recommends dose adjustment, flags interactions
- Medication History Taking: On admission, to prevent omission/duplication errors
- Discharge Counselling: Ensures patient understands take-home medication regimen
- Home Medication Review (HMR): For chronic/elderly patients
6.3 Special Population Counselling
- Geriatric: Simplified regimen, large-print label, caregiver involvement, polypharmacy review
- Pediatric: Weight/BSA-based dosing explained to caregiver
- Pregnancy/Lactation — FDA Pregnancy Categories:
- A: No risk shown in controlled studies
- B: No risk in animal studies, no human data / animal risk but human studies show no risk
- C: Risk not ruled out; animal studies show adverse effect
- D: Positive evidence of human risk, but benefit may outweigh
- X: Contraindicated in pregnancy
SECTION 7: DRUG INFORMATION SERVICES (DIS)
7.1 Sources of Drug Information (3-tier — must memorize)
Exam Tip: Understand and memorize the three tiers of drug information sources.
- Primary: Original research — journal articles, clinical trial reports, case reports
- Secondary: Indexing/abstracting services — PubMed/MEDLINE, Embase, International Pharmaceutical Abstracts (IPA), Google Scholar
- Tertiary: Compiled references — Martindale: The Complete Drug Reference, USP-DI, AHFS Drug Information, British National Formulary (BNF), CIMS, MIMS, Goodman & Gilman
7.2 Functions of a Drug Information Centre (DIC)
- Answering queries from physicians/nurses/patients, publishing hospital drug bulletins/newsletters, supporting PTC decisions, drug utilization evaluation, ADR causality assessment support
7.3 Poison Information Centre
- Provides emergency information on poisoning management, antidotes, toxicology consultation (e.g., NPIC AIIMS Delhi is India's national centre)
SECTION 8: THERAPEUTIC DRUG MONITORING (TDM) — FULL DETAIL
8.1 Principle & Rationale
- Measures plasma drug concentration to individualize dosing for drugs with Narrow Therapeutic Index (NTI)
8.2 Criteria for TDM Candidacy
- Narrow therapeutic index, significant inter-patient PK variability, established concentration-effect relationship, difficulty in clinical assessment of efficacy/toxicity, serious consequences of toxicity/sub-therapeutic levels
8.3 Pharmacokinetic Formulas for TDM (High-yield numericals)
Exam Tip: These pharmacokinetic formulas are high-yield for numerical problems.
- Loading Dose: LD = (Vd × Target Cp) / F
- Maintenance Dose: MD = (Cl × Target Cp × τ) / F (τ = dosing interval)
- Half-life: t½ = 0.693/Ke (Ke = elimination rate constant)
- Steady state: Reached after 4–5 half-lives
- Volume of Distribution (Vd): Vd = Dose/C₀
- Clearance (Cl): Cl = Ke × Vd
8.4 TDM Drug List with Therapeutic Ranges (MUST MEMORIZE)
Exam Tip: This table contains critical information; it is essential to memorize these drugs and their therapeutic ranges.
| Drug | Therapeutic Range | Key Note |
|---|
| Digoxin | 0.5–2.0 ng/mL | Narrow TI; toxicity = arrhythmia, visual halos |
| Phenytoin | 10–20 µg/mL | Zero-order (non-linear) kinetics near therapeutic range |
| Lithium | 0.6–1.2 mEq/L | Trough sample 12 hrs post-dose |
| Theophylline | 10–20 µg/mL | Toxicity: seizures, arrhythmia |
| Carbamazepine | 4–12 µg/mL | Autoinduces its own metabolism |
| Valproic acid | 50–100 µg/mL | Hepatotoxicity risk |
| Gentamicin | Peak 5–10, Trough <2 µg/mL | Nephro/ototoxic |
| Vancomycin | Trough 10–20 µg/mL | Nephrotoxic, "Red man syndrome" (infusion-related, not allergy) |
| Cyclosporine | 100–400 ng/mL | Transplant rejection prevention |
| Amikacin | Peak 20–30, Trough <10 µg/mL | Aminoglycoside |
8.5 Sampling Timing
- Trough: Just before next dose (steady state) — most common sample
- Peak: After absorption/distribution complete (drug-specific, e.g., 1 hr post-IV infusion end for aminoglycosides)
SECTION 9: PHARMACOVIGILANCE & ADR MONITORING (Full Detail)
9.1 Key Definitions (WHO)
- ADR (Adverse Drug Reaction): Noxious, unintended response to a drug at doses normally used
- ADE (Adverse Drug Event): Any untoward occurrence, may/may not be drug-related
- Side Effect: Known, predictable pharmacological effect at normal dose
- Signal: Reported information on possible causal relationship, previously unknown/incompletely documented
9.2 Classification of ADRs — Rawlins-Thompson (Type A–F) — MUST MEMORIZE
Exam Tip: The Rawlins-Thompson classification of ADRs is a high-yield topic. Understand and memorize each type.
- Type A (Augmented): Dose-related, predictable, common, low mortality (e.g., hypoglycemia with insulin, bleeding with warfarin)
- Type B (Bizarre): Not dose-related, unpredictable, immunologic/idiosyncratic, high mortality (e.g., anaphylaxis, Stevens-Johnson syndrome)
- Type C (Chronic): Related to cumulative dose over time (e.g., analgesic nephropathy, osteoporosis with steroids)
- Type D (Delayed): Delayed onset, appears after drug stopped/years later (e.g., teratogenicity, carcinogenicity)
- Type E (End of use/Withdrawal): Occurs on abrupt discontinuation (e.g., corticosteroid adrenal crisis, rebound hypertension with clonidine)
- Type F (Failure of therapy): Unexpected treatment failure, often dose-related, frequently due to drug interaction (e.g., OCP failure with enzyme inducers)
9.3 Causality Assessment Scales
- Naranjo Algorithm: 10-question scoring scale; categorizes as Definite (≥9), Probable (5–8), Possible (1–4), Doubtful (≤0)
- WHO-UMC Causality Categories: Certain, Probable/Likely, Possible, Unlikely, Conditional/Unclassified, Unassessable/Unclassifiable
9.4 Severity & Preventability Assessment
- Hartwig's Severity Scale: Grades ADR from mild (Level 1) to fatal (Level 7)
- Modified Schumock & Thornton criteria: Assesses preventability of ADR
9.5 PvPI (Pharmacovigilance Programme of India)
- National Coordinating Centre (NCC-PvPI): Indian Pharmacopoeia Commission (IPC), Ghaziabad
- ADR Monitoring Centres (AMCs) at hospitals across India report suspected ADRs via the "Suspected Adverse Drug Reaction Reporting Form"
- Reports flow: AMC → NCC-PvPI → global database (WHO-UMC VigiBase, Uppsala Monitoring Centre, Sweden)
9.6 Reporting Obligations
- CDSCO/DCGI mandates ADR reporting for marketed drugs and clinical trials (Serious Adverse Events — SAEs — reported within 24 hours by investigator, 14/30 days for expedited reporting to DCGI per New Drugs and Clinical Trial Rules 2019)
SECTION 10: MEDICATION ERRORS & PATIENT SAFETY
10.1 Types of Medication Errors
- Prescribing error, transcription error, dispensing error, administration error, monitoring error
10.2 NCC MERP Classification (Categories A–I)
- A: Circumstance/capacity for error (no error occurred)
- B–D: Error occurred, no harm
- E–H: Error occurred, harm caused (temporary to permanent)
- I: Error contributed to patient death
10.3 Error Prevention Strategies
- Computerized Physician Order Entry (CPOE), Bar-code medication administration (BCMA), Tall Man lettering, independent double-check for high-alert drugs, "5 Rights" of medication administration (Right patient, drug, dose, route, time — sometimes extended to 7 or 9 rights including documentation and reason)
10.4 High-Alert Medications (ISMP list — high-yield)
- Insulin, opioids, anticoagulants (heparin, warfarin), concentrated electrolytes (KCl injection), neuromuscular blocking agents, chemotherapy drugs
SECTION 11: COLD CHAIN & STORAGE MANAGEMENT
11.1 Cold Chain Principle
- Maintaining temperature-sensitive products (vaccines, biologicals, insulin) within specified range from manufacture to point of use (WHO Cold Chain)
11.2 Storage Temperatures (Memorize)
- Vaccines (most, e.g., DPT, Hepatitis B): 2–8°C
- OPV (Oral Polio Vaccine): –15°C to –25°C (freezer)
- Insulin: 2–8°C unopened; room temp (≤25–30°C) after opening, discard per label (usually 28 days)
- Blood/blood products: 2–6°C (whole blood/RBC); FFP frozen at –18°C or below; platelets at 20–24°C with agitation
11.3 General Storage Conditions (IP definitions — cross-subject relevance)
- Cool place: 8–15°C
- Room temperature: 15–25°C (or up to 30°C per label)
- Refrigerator: 2–8°C
- Freezer: –20°C ± 5°C
- Protection from light: Amber/opaque containers
11.4 Cold Chain Equipment
- Walk-in cooler (WIC), walk-in freezer (WIF), Ice-Lined Refrigerator (ILR), deep freezer, vaccine carrier, cold box, ice packs, temperature data loggers (continuous monitoring, especially for vaccine cold chain breach investigation)
11.5 Narcotic & Psychotropic Storage (NDPS Act linkage)
- Double-lock system mandatory, register maintained, physical stock verified periodically, controlled access
SECTION 12: RATIONAL DRUG USE (RDU) & ESSENTIAL MEDICINES
12.1 WHO Definition of Rational Drug Use
- Patients receive medicines appropriate to clinical needs, in doses meeting individual requirements, for adequate period, at lowest cost to them/community
12.2 WHO Core Drug Use Indicators
- Prescribing indicators: Average number of drugs per encounter, % prescribed by generic name, % encounters with antibiotic prescribed, % encounters with injection prescribed, % drugs from Essential Medicines List (EML)
- Patient care indicators: Average consultation time, average dispensing time, % drugs actually dispensed, % drugs adequately labeled, patient knowledge of correct dosage
- Facility indicators: Availability of copy of EML/formulary, % key drugs actually in stock
12.3 National List of Essential Medicines (NLEM)
- India's NLEM (latest revision 2022) — basis for price control under DPCO (cross-link Subject 1)
- Concept: Medicines that satisfy priority healthcare needs of majority population, selected on efficacy, safety, cost-effectiveness
12.4 Drug Utilization Evaluation (DUE)/Review (DUR)
- Systematic, criteria-based evaluation of drug use — Retrospective (after use), Concurrent (during therapy), Prospective (before dispensing)
SECTION 13: HOSPITAL ACCREDITATION & QUALITY STANDARDS
13.1 NABH (National Accreditation Board for Hospitals, India)
- Pharmacy-relevant chapters: Management of Medication (MOM) — covers storage, prescribing, dispensing, administration, monitoring, high-alert drugs, look-alike/sound-alike drugs, narcotic storage
13.2 JCI (Joint Commission International) — global equivalent
- International Patient Safety Goals include: Improve medication safety (look-alike/sound-alike drugs), reduce harm from high-alert medications
13.3 Good Distribution Practice (GDP) at hospital level
- Ensures quality maintained throughout storage/distribution within hospital (temperature control, FEFO — First Expiry First Out, damaged/expired stock Quarantine.
